Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27030396 | 1.00 | SLC6A4 (0.35) | SLC6A4PSMB5CHRNA7RXFP1TNF | |
| SCHEMBL30945561 | 0.84 | SLC6A4 (0.51) | SLC6A4CHRNA7TNF | |
| SCHEMBL29830542 | 0.83 | CHRNA7 (0.37) | SLC6A4PSMB5CHRNA7 | |
| SCHEMBL27030472 | 0.81 | RXFP1 (0.31) | RXFP1TNF | |
| SCHEMBL27030256 | 0.81 | RXFP1 (0.31) | RXFP1TNF | |
| SCHEMBL29829880 | 0.81 | RXFP1 (0.31) | RXFP1TNF | |
| SCHEMBL27030430 | 0.80 | NPC1 (0.37) | — | |
| SCHEMBL29830347 | 0.79 | EGFR (0.35) | PSMB5CHRNA7 | |
| SCHEMBL27030249 | 0.79 | EGFR (0.35) | PSMB5CHRNA7 | |
| SCHEMBL30945553 | 0.76 | ALDH1A1 (0.45) | SLC6A4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199613-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-06-20 | — | — | US | disclosed |
| EP-4308564-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197789-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199613-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | SLC6A4 4139/4885PSMB5 1517/4885CHRNA7 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.